SecurityCTSO / Cytosorbents Corp (23283X206)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding29,471,343 shares (as of 2017-12-31)
Total Insiders11
Total Directors6
Total Officers5

Stock Insider Trading (from SEC Form 4)

Cytosorbents Corp insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CTSO / Cytosorbents Corp insiders include BARTLETT ROBERT HAWES, Capponi Vincent, Jones Edward Raymond, Gunton James T., NJTC INVESTMENT FUND, LP, and BLOCH KATHLEEN P., Kraus Al, Mortensen Eric R. BATOR MICHAEL G., Sobel Alan D., Chan Phillip P., .

Insider Roster

Insider Dir Off 10% Shares Owned
Capponi Vincent Chief Operating Officer
X 317,551
BLOCH KATHLEEN P. Chief Financial Officer
X 262,304
Sobel Alan D. Director
X 69,300
BATOR MICHAEL G. Director
X 73,800
Jones Edward Raymond Director
X 71,800
Kraus Al Director
X 125,046
Mortensen Eric R. Chief Medical Officer
X 36,500
Chan Phillip P. President and CEO, Director
X X 440,713
BARTLETT ROBERT HAWES Chief Medical Officer
X
NJTC INVESTMENT FUND, LP 10% Owner
X
Gunton James T. Director, 10% Owner
X X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-16 4 Capponi Vincent S X D 9.00 -4,846 317,551 2,857,959
2018-05-16 4 Capponi Vincent M X D 0.875 4,846 322,397
2018-05-17 4 Capponi Vincent S X D 10.00 -20,000 317,551 3,175,510
2018-05-17 4 Capponi Vincent S X D 10.00 -8,000 337,551 3,375,510
2018-05-17 4 Capponi Vincent M X D 0.875 20,000 345,551
2018-05-17 4 Capponi Vincent M X D 4.20 8,000 325,551
2018-05-15 4 Capponi Vincent S X D 9.00 -3,154 317,551 2,857,959
2018-05-15 4 Capponi Vincent S X D 9.00 -4,000 320,705 2,886,345
2018-05-15 4 Capponi Vincent M X D 0.875 3,154 324,705
2018-05-15 4 Capponi Vincent M X D 4.20 4,000 321,551
2018-05-15 4 BLOCH KATHLEEN P. S X D 8.75 -12,400 262,304 2,295,160
2018-05-15 4 BLOCH KATHLEEN P. M X D 4.69 12,400 274,704
2018-05-16 4 BLOCH KATHLEEN P. S X D 9.00 -12,400 262,304 2,360,736
2018-05-16 4 BLOCH KATHLEEN P. M X D 4.69 12,400 274,704
2018-05-14 4 BLOCH KATHLEEN P. S X D 8.50 -10,000 262,304 2,229,584
2018-05-14 4 BLOCH KATHLEEN P. M X D 2.90 10,000 272,304
2018-03-15 4 Kraus Al A D 3,300 125,046
2018-03-15 4 Jones Edward Raymond A D 3,300 71,800
2018-03-15 4 BATOR MICHAEL G. A D 3,300 73,800
2018-03-15 4 Sobel Alan D. A D 3,300 69,300
2018-04-17 4 BLOCH KATHLEEN P. S X D 8.25 -120 262,304 2,164,008
2018-04-17 4 BLOCH KATHLEEN P. M X D 4.69 120 262,424
2018-02-21 4 BLOCH KATHLEEN P. S X D 8.00 -10,000 267,870 2,142,960
2018-02-21 4 BLOCH KATHLEEN P. M X D 2.90 10,000 277,870
2018-03-15 4 Mortensen Eric R. A D 20,000 36,500
2018-03-15 4 BLOCH KATHLEEN P. A D 8,800 266,870
2018-03-15 4 Chan Phillip P. A D 10,300 440,713
2018-03-15 4 Capponi Vincent A D 10,100 317,551
2018-03-15 4 BLOCH KATHLEEN P. S X D 8.25 -11,176 259,070 2,137,328
2018-03-15 4 BLOCH KATHLEEN P. M X D 4.69 11,176 270,246
2018-03-13 4 BLOCH KATHLEEN P. S X D 8.25 -1,104 259,070 2,137,328
2018-03-13 4 BLOCH KATHLEEN P. M X D 4.69 1,104 260,174
2018-02-28 4 Mortensen Eric R. A D 14,000 16,500
2018-02-28 4 Chan Phillip P. A D 43,000 430,413
2018-02-28 4 BLOCH KATHLEEN P. A D 34,700 259,070
2018-02-28 4 Capponi Vincent A D 38,000 307,451
2018-01-16 4 Capponi Vincent F D 7.80 -35,257 283,805
2018-01-16 4 Capponi Vincent M D 6.25 44,000 319,062
2018-01-12 4 BLOCH KATHLEEN P. S X D 7.75 -12,400 237,638 1,841,694
2018-01-12 4 BLOCH KATHLEEN P. M X D 4.69 12,400 250,038
2018-01-08 4 BLOCH KATHLEEN P. S X D 7.50 -10,000 237,638 1,782,285
2018-01-08 4 BLOCH KATHLEEN P. S X D 7.25 -12,400 247,638 1,795,376
2018-01-08 4 BLOCH KATHLEEN P. S X D 7.15 -10,000 260,038 1,859,272
2018-01-08 4 BLOCH KATHLEEN P. M X D 4.69 12,400 270,038
2018-01-08 4 BLOCH KATHLEEN P. M X D 2.90 20,000 257,638
2017-11-27 4 Capponi Vincent M D 4.20 4,000 275,062
2017-11-27 4 Capponi Vincent S D 7.00 -4,000 271,062 1,897,434
2017-06-09 4 Mortensen Eric R. P D 4.0398 2,500 2,500 10,100
2017-06-09 4 BATOR MICHAEL G. P D 4.12 1,500 70,500 290,460
2017-06-08 4 Jones Edward Raymond P D 3.9995 2,000 68,500 273,966
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

14h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

14h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Cytosorbents' (CTSO) CEO Phillip Chan on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good afternoon and welcome to the Cytosorbents' First Quarter 2018 financial and operating results conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the Company's request.

Biotech Forum Daily Digest For March 9th

2018-03-09 seekingalpha
Both the overall market and the main biotech indices managed a slight gain Thursday as new proposed tariffs were better than the worse case scenario. (93-0)

Cytosorbents Corp 2017 Q4 - Results - Earnings Call Slides

2018-03-09 seekingalpha
The following slide deck was published by Cytosorbents Corp in conjunction with their 2017 Q4 earnings call.

Cytosorbents' (CTSO) CEO Phillip Chan on Q4 2017 Results - Earnings Call Transcript

2018-03-09 seekingalpha
Good afternoon and welcome to the CytoSorbents 2017 Financial and Operating Results Conference Call. At this time all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded as the Company's request. At this time, I'd like to turn the call over to our moderator, Jeremy Feffer. Please go ahead, Mr.

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

2018-02-15 reuters
* CYTOSORBENTS CORP - ‍BIOCON HAS EXCLUSIVE RIGHTS TO DISTRIBUTE CYTOSORB IN MALAYSIA, WHERE CYTOSORB IS ALREADY REGISTERED​